The UK and US have reached a significant commercial pact that will keep no import taxes on UK drug shipments being sold in the American market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to raise expenditure on drugs through the NHS. This move guarantees that tariffs on these crucial exports will be held at nothing for a period of three years.
This deal is in response to earlier statements to significantly raise tariffs on patented pharmaceutical imports, with increases discussed up to 100%.
"This deal between the UK strengthens the global environment for cutting-edge drugs and brings long-overdue balance to U.S.–U.K. drug exports," a release declared.
Commercial Importance
Drugs represent one of the Britain's most significant exports to the US, which is clearly the biggest buyer for leading UK drugmakers.
Trade data indicate that in the year prior to last September, the UK shipped medicines totaling £11.1bn to the US. This value accounted for nearly one-fifth of all goods exports in that span.
"This guarantee protects work, increases investment and paves the way for the UK to become a international leader for medical research," a minister stated.
Specific NHS Changes
The deal entails several specific changes from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to increase total NHS spending on drugs from 0.3% of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount manufacturers must refund to the NHS to prevent overspending will be capped at fifteen percent. Last year, repayments topped twenty percent.
Broader Context
This agreement follows a long-running row between the sector and the ministers over drug pricing and NHS adoption.
These tensions were exacerbated by claims that US consumers were charged significantly more for the same drugs than people in the UK and Europe.
Recently, several significant drug company projects in the UK have been halted or abandoned, while substantial investments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS had to spend more on treatments, noting that its spending on drugs had declined as a percentage of its resources over the last ten years.
